Barclays
RXRX icon

Barclays’s Recursion Pharmaceuticals RXRX Stock Holding History

Barclays’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-60,000
Closed -$450K – 5445
2024
Q2 		$450K Buy
+60,000
New +$523K ﹤0.01% 3098

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's RXRX Position: Q1 2026 in Review

Barclays reduced its Recursion Pharmaceuticals (RXRX) stake by 90% in Q1 2026, selling an estimated $5.09M and leaving 153,271 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #3223.

Barclays first reported a position in RXRX in Q1 2022 and has held it in 17 quarters since. The position peaked at $7.57M in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Barclays held 153,271 shares of Recursion Pharmaceuticals worth $471K as of Q1 2026.
  • Barclays sold 1,315,991 Recursion Pharmaceuticals shares in Q1 2026, an estimated $5.09M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3223 holding.
  • Barclays first reported a position in Recursion Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Recursion Pharmaceuticals position peaked at $7.57M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.